{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:17:13Z","timestamp":1762431433189},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whilst various remedial human monoclonal antibodies have been developed to treat the potentially life-threatening systemic complications associated with anthrax infection, an optimal and universally effective administration route has yet to be established. In the later stages of infection when antibody administration by injection is more likely to fail one possible route to improve outcome is via the use of an antibody-bound, adsorbent haemoperfusion device. We report here the development of an adsorbent macroporous polymer column containing immobilised <jats:italic>B<\/jats:italic>. <jats:italic>anthracis exotoxin-specific<\/jats:italic> antibodies, PANG (a non-glycosylated, version of a plant-produced human monoclonal antibody) and Valortim (a fully human monoclonal N-linked glycosylated antibody), for removal of anthrax protective antigen (PA) from freshly frozen human plasma and human whole blood. In addition, we have demonstrated that continuous extracorporeal blood recirculation through a Valortim-bound haemoperfusion column significantly reduced the blood plasma concentration of anthrax PA over 2 hours using an <jats:italic>in vivo<\/jats:italic> PA rat infusion model. This work provides proof-of-concept evidence to support the development of such alternative detoxification platforms.<\/jats:p>","DOI":"10.1038\/s41598-018-25678-0","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T13:35:45Z","timestamp":1525786545000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bioinspired detoxification of blood: The efficient removal of anthrax toxin protective antigen using an extracorporeal macroporous adsorbent device"],"prefix":"10.1038","volume":"8","author":[{"given":"Ganesh","family":"Ingavle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Mikhalovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Sandeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"25678_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJM199909093411107","volume":"341","author":"TC Dixon","year":"1999","unstructured":"Dixon, T. C., Meselson, M., Guillemin, J. & Hanna, P. C. Anthrax. N Engl J Med 341, 815\u201326 (1999).","journal-title":"N Engl J Med"},{"key":"25678_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/385833a0","volume":"385","author":"C Petosa","year":"1997","unstructured":"Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H. & Liddington, R. C. Crystal structure of the anthrax toxin protective antigen. Nat. 385, 833\u20138 (1997).","journal-title":"Nat."},{"key":"25678_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/n35101999","volume":"414","author":"KA Bradley","year":"2001","unstructured":"Bradley, K. A., Mourez, J., Mourez, M., Collier, R. J. & Young, J. A. Identification of the cellular receptor for anthrax toxin. Nat. 414, 225\u20139 (2001).","journal-title":"Nat."},{"key":"25678_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrmicro977","volume":"2","author":"GJ Rainey","year":"2004","unstructured":"Rainey, G. J. & Young, J. A. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2, 721\u20136 (2004).","journal-title":"Nat Rev Microbiol"},{"key":"25678_CR5","doi-asserted-by":"crossref","unstructured":"Panchal, R. G. et al. Purified bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity. J Biol Chem 280, 10834\u20139 (2005).","DOI":"10.1074\/jbc.M412210200"},{"key":"25678_CR6","doi-asserted-by":"crossref","unstructured":"Ezzell, J. J. W. & Abshire, T. G. Serum protease cleavage of bacillus anthracis protective antigen. J Gen Microbiol 138, 543\u20139 (1992).","DOI":"10.1099\/00221287-138-3-543"},{"key":"25678_CR7","first-page":"33","volume":"271","author":"AM Friedlander","year":"2002","unstructured":"Friedlander, A. M., Welkos, S. L. & Ivins, B. E. Anthrax vaccines. Curr Top Microbiol Immunol 271, 33\u201360 (2002).","journal-title":"Curr Top Microbiol Immunol"},{"key":"25678_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1086\/523578","volume":"46","author":"JD Grabenstein","year":"2008","unstructured":"Grabenstein, J. D. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 46, 129\u201336 (2008).","journal-title":"Clin Infect Dis"},{"key":"25678_CR9","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","volume":"287","author":"TV Inglesby","year":"2002","unstructured":"Inglesby, T. V. et al. Anthrax as a biological weapon, 2002: updated recommendations for management. Jama 287, 2236\u201352 (2002).","journal-title":"Jama"},{"key":"25678_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid0706.010604","volume":"7","author":"JA Jernigan","year":"2001","unstructured":"Jernigan, J. A. et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the united states. Emerg Infect Dis 7, 933\u201344 (2001).","journal-title":"Emerg Infect Dis"},{"key":"25678_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4161\/hv.9777","volume":"5","author":"LW Baillie","year":"2009","unstructured":"Baillie, L. W. Is new always better than old?: The development of human vaccines for anthrax. Hum Vaccin 5, 806\u201316 (2009).","journal-title":"Hum Vaccin"},{"key":"25678_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0168-1656(95)00092-5","volume":"44","author":"AV Stepanov","year":"1996","unstructured":"Stepanov, A. V., Marinin, L. I., Pomerantsev, A. P. & Staritsin, N. A. Development of novel vaccines against anthrax in man. J Biotechnol 44, 155\u201360 (1996).","journal-title":"J Biotechnol"},{"key":"25678_CR13","doi-asserted-by":"crossref","unstructured":"Froude, n., J. W., Thullier, P. & Pelat, T. Antibodies against anthrax: mechanisms of action and clinical applications. Toxins (Basel) 3, 1433\u201352.","DOI":"10.3390\/toxins3111433"},{"key":"25678_CR14","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/iai.65.12.5171-5175.1997","volume":"65","author":"SF Little","year":"1997","unstructured":"Little, S. F., Ivins, B. E., Fellows, P. F. & Friedlander, A. M. Passive protection by polyclonal antibodies against bacillus anthracis infection in guinea pigs. Infect Immun 65, 5171\u20135 (1997).","journal-title":"Infect Immun"},{"key":"25678_CR15","doi-asserted-by":"crossref","unstructured":"Hendricks, K. A. et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 20 (2014).","DOI":"10.3201\/eid2002.130687"},{"key":"25678_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","volume":"64","author":"WA Bower","year":"2015","unstructured":"Bower, W. A. et al. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64, 1\u201322 (2015).","journal-title":"MMWR Recomm Rep"},{"issue":"Suppl","key":"25678_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4161\/hv.7.0.14586","volume":"7","author":"V Mett","year":"2011","unstructured":"Mett, V. et al. A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from b. anthracis spore challenge. Hum Vaccin 7(Suppl), 183\u201390 (2011).","journal-title":"Hum Vaccin"},{"key":"25678_CR18","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.1128\/IAI.00712-06","volume":"74","author":"L Vitale","year":"2006","unstructured":"Vitale, L. et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infection and Immunity 74, 5840\u20135847 (2006).","journal-title":"Infection and Immunity"},{"key":"25678_CR19","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1128\/CVI.05059-11","volume":"18","author":"V Riddle","year":"2011","unstructured":"Riddle, V. et al. Phase i study evaluating the safety and pharmacokinetics of mdx-1303, a fully human monoclonal antibody against bacillus anthracis protective antigen, in healthy volunteers. Clinical and Vaccine Immunology 18, 2136\u20132142 (2011).","journal-title":"Clinical and Vaccine Immunology"},{"key":"25678_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nbt0602-597","volume":"20","author":"JA Maynard","year":"2002","unstructured":"Maynard, J. A. et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20, 597\u2013601 (2002).","journal-title":"Nat Biotechnol"},{"key":"25678_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","volume":"361","author":"TS Migone","year":"2009","unstructured":"Migone, T. S. et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361, 135\u201344 (2009).","journal-title":"N Engl J Med"},{"key":"25678_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1128\/AAC.04606-14","volume":"59","author":"TS Migone","year":"2015","unstructured":"Migone, T. S. et al. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax. Antimicrob Agents Chemother 59, 1145\u201351 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"25678_CR23","doi-asserted-by":"crossref","unstructured":"Rubinson, L. M. P., Corey, A. & Hanfling, D. Estimation of time period for effective human inhalational anthrax treatment including antitoxin therapy. PLoS Curr 9 (2017).","DOI":"10.1371\/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d"},{"key":"25678_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2353\/ajpath.2006.051330","volume":"169","author":"DJ Stearns-Kurosawa","year":"2006","unstructured":"Stearns-Kurosawa, D. J., Lupu, F., Taylor, J., Taylor, F. B., Kinasewitz, G. & Kurosawa, S. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol 169, 433\u201344 (2006).","journal-title":"Am J Pathol"},{"key":"25678_CR25","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1128\/IAI.01632-06","volume":"75","author":"J Tessier","year":"2007","unstructured":"Tessier, J. et al. Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from bacillus anthracis. Infect Immun 75, 1895\u2013903 (2007).","journal-title":"Infect Immun"},{"key":"25678_CR26","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/IAI.00170-10","volume":"78","author":"JK Iyer","year":"2010","unstructured":"Iyer, J. K. et al. Inflammatory cytokine response to bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun 78, 2418\u201328 (2010).","journal-title":"Infect Immun"},{"key":"25678_CR27","unstructured":"Hermanson, G. T. Immobilized affinity ligand techniques (1992)."},{"key":"25678_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nbt0793-825","volume":"11","author":"TM Spitznagel","year":"1993","unstructured":"Spitznagel, T. M. & Clark, D. S. Surface-density and orientation effects on immobilized antibodies and antibody fragments. Nature Biotechnology 11, 825\u20139 (1993).","journal-title":"Nature Biotechnology"},{"key":"25678_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF01243043","volume":"128","author":"SV Rao","year":"1998","unstructured":"Rao, S. V., Anderson, K. W. & Bachas, L. G. Oriented immobilization of proteins. Mikrochimica Acta 128, 127\u2013143 (1998).","journal-title":"Mikrochimica Acta"},{"key":"25678_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0022-1759(78)90133-3","volume":"24","author":"DM Gersten","year":"1978","unstructured":"Gersten, D. M. & Marchalonis, J. J. A rapid, novel method for the solid-phase derivatization of igg antibodies for immune-affinity chromatography. J Immunol Methods 24, 305\u20139 (1978).","journal-title":"J Immunol Methods"},{"key":"25678_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0378-4347(98)00434-4","volume":"722","author":"J Turkova","year":"1999","unstructured":"Turkova, J. Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function. J Chromatogr B Biomed Sci Appl 722, 11\u201331 (1999).","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"25678_CR32","doi-asserted-by":"publisher","first-page":"29R","DOI":"10.1039\/an996210029r","volume":"121","author":"B Lu","year":"1996","unstructured":"Lu, B., Smyth, M. R. & O'Kennedy, R. Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Analyst 121, 29R\u201332R (1996).","journal-title":"Analyst"},{"key":"25678_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0956-5663(00)00115-9","volume":"15","author":"S Babacan","year":"2000","unstructured":"Babacan, S., Pivarnik, P., Letcher, S. & Rand, A. G. Evaluation of antibody immobilization methods for piezoelectric biosensor application. Biosens Bioelectron 15, 615\u201321 (2000).","journal-title":"Biosens Bioelectron"},{"key":"25678_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0956-5663(96)00074-7","volume":"12","author":"GP Anderson","year":"1997","unstructured":"Anderson, G. P., Jacoby, M. A., Ligler, F. S. & King, K. D. Effectiveness of protein a for antibody immobilization for a fiber optic biosensor. Biosens Bioelectron 12, 329\u201336 (1997).","journal-title":"Biosens Bioelectron"},{"key":"25678_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/bit.10760","volume":"84","author":"R Danczyk","year":"2003","unstructured":"Danczyk, R. et al. Comparison of antibody functionality using different immobilization methods. Biotechnology and Bioengineering 84, 215\u2013223 (2003).","journal-title":"Biotechnology and Bioengineering"},{"key":"25678_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.biomaterials.2015.01.039","volume":"50","author":"GC Ingavle","year":"2015","unstructured":"Ingavle, G. C. et al. Affinity binding of antibodies to supermacroporous cryogel adsorbents with immobilized protein a for removal of anthrax toxin protective antigen. Biomaterials 50, 140\u201353 (2015).","journal-title":"Biomaterials"},{"key":"25678_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0378-4347(00)00499-0","volume":"752","author":"D Josic","year":"2001","unstructured":"Josic, D., Buchacher, A. & Jungbauer, A. Monoliths as stationary phases for separation of proteins and polynucleotides and enzymatic conversion. of Chromatography B 752, 191\u2013205 (2001).","journal-title":"of Chromatography B"},{"key":"25678_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep21154","volume":"6","author":"IN Savina","year":"2016","unstructured":"Savina, I. N., Ingavle, G. C., Cundy, A. B. & Mikhalovsky, S. V. A simple method for the production of large 3d macroporous hydrogels for advanced biotechnological, medical and environmental applications. Sci Rep 6, 21154 (2016).","journal-title":"Sci Rep"},{"key":"25678_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cis.2012.11.001","volume":"187-188","author":"VM Gun\u2019ko","year":"2013","unstructured":"Gun\u2019ko, V. M., Savina, I. N. & Mikhalovsky, S. V. Cryogels: morphological, structural and adsorption characterisation. Adv Colloid Interface Sci 187-188, 1\u201346 (2013).","journal-title":"Adv Colloid Interface Sci"},{"key":"25678_CR40","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1039\/c0sm01304h","volume":"7","author":"IN Savina","year":"2011","unstructured":"Savina, I. N. et al. Porous structure and water state in cross-linked polymer and protein cryo-hydrogels. Soft Matter 7, 4276\u20134283 (2011).","journal-title":"Soft Matter"},{"key":"25678_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0021-9673(02)00072-9","volume":"954","author":"HF Zou","year":"2002","unstructured":"Zou, H. F., Huang, X. D., Ye, M. L. & Luo, Q. Z. Monolithic stationary phases for liquid chromatography and capillary electrochromatography. of Chromatography A 954, 5\u201332 (2002).","journal-title":"of Chromatography A"},{"key":"25678_CR42","doi-asserted-by":"publisher","unstructured":"Zheng, Y. et al. Rapid adsorption of proinflammatory cytokines by graphene nanoplatelets and their composites for extracorporeal detoxification. J of Nanomater https:\/\/doi.org\/10.1155\/2018\/6274072.","DOI":"10.1155\/2018\/6274072"},{"key":"25678_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1662-9","volume":"21","author":"K Kogelmann","year":"2017","unstructured":"Kogelmann, K., Jarczak, D., Scheller, M. & Druner, M. Hemoadsorption by cytosorb in septic patients: a case series. Crit Care 21, 74 (2017).","journal-title":"Crit Care"},{"key":"25678_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000375229","volume":"38","author":"S Buttner","year":"2014","unstructured":"Buttner, S. et al. Extracorporeal virus elimination for the treatment of severe ebola virus disease\u2013first experience with lectin affinity plasmapheresis. Blood Purif 38, 286\u201391 (2014).","journal-title":"Blood Purif"},{"key":"25678_CR45","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1128\/IAI.01242-06","volume":"75","author":"MG Stokes","year":"2007","unstructured":"Stokes, M. G. et al. Oral administration of a salmonella enterica-based vaccine expressing bacillus anthracis protective antigen confers protection against aerosolized b. anthracis. Infect Immun 75, 1827\u201334 (2007).","journal-title":"Infect Immun"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25678-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25678-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:12:11Z","timestamp":1671599531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-25678-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["25678"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-25678-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,14]]},"assertion":[{"value":"7 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7518"}}